December 15, 2016
BD launches new prefillable glass syringe
BD has launched the BD Neopak 2.25 mL prefillable glass syringe, specifically designed for biopharmaceutical manufacturers that develop, manufacture and…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 15, 2016
Lilly/Boehringer Ingelheim: A long-acting basal insulin available in U.S.
Eli Lilly and Boehringer Ingelheim Pharmaceuticals have announced that Basaglar (insulin glargine injection 100 units/mL) is available by prescription in…
December 15, 2016
Survey: How would you improve pharmaceuticaldaily?
As some of you might know, pharmaceuticaldaily.com has recently redesigned its website as it added some new features and has…
December 15, 2016
COMP gives positive opinion on Hansa Medical’s orphan drug
Hansa Medical, a biopharmaceutical company focusing on novel immunomodulatory enzymes, has announced that the Committee for Orphan Medicinal Products (COMP)…
December 15, 2016
Results of filgotinib Gilead’s study in Chron’s
Galapagos has tested its filgotinib – JAK1 inhibitor – in a phase 2 study, for the patients with Chron’s disease, and…
December 15, 2016
NOXXON/Merck to study drugs combination in cancer treatment
NOXXON Pharma N.V. has announced a collaboration with Merck & Co. (MSD), Inc, under which the two companies will collaborate…
December 15, 2016
Bioven gets green light for NSC cancer drug testing patient enrolment
A cancer-focused drug-maker Bioven can now enrol patients in the USA in its international Phase III trial of EGF-PTI, in…
December 15, 2016
Kiadis Pharma starts a P I/II clinical trial for thalassemia treatment
Kiadis Pharma N.V., a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders…
December 15, 2016
TiGenix raises $35.65M proceeds with NASDAQ IPO
A biopharmaceutical company TiGenix focused on allogeneic expanded stem cells, has raised $35.65 million gross proceeds from the sale of 2,300,000 American Depository…
December 15, 2016
Argenx launches P I/II clinical trial for acute myeloid leukemia treatment
Argenx, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe…